Beta Bionics Q3 sales rise 30% to $35.5 million; net loss widens to $24.4 million
Beta Bionics reported third-quarter 2026 net sales of $35.5 million, up 30% from a year earlier, but its net loss widened to $24.4 million from $14.2 million. The company narrowed its full-year 2026 revenue guidance to $124 million to $126 million, raising the low end, while noting a possible deferral of up to $8.5 million of fourth-quarter revenue as some users await the Mint launch.
Key points
- Net sales were $35.5 million, up 30% from $27.3 million; pharmacy benefit plan channel sales rose 118% to $13.6 million.
- Net loss was $24.4 million, or $0.52 per share, compared with $14.2 million, or $0.33 per share, in the third quarter of 2025.
- 2026 revenue guidance is $124 million to $126 million, up from $121 million to $126 million at the low end; gross margin guidance of 58.5% to 59.5% was unchanged.
- The company withdrew its 3D Intelligence 510(k) application and plans to submit a revised one in mid-Q4 2026; it also completed a public offering netting about $161.3 million.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.